文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

多黏菌素B血液灌流对严重脓毒症和脓毒性休克患者死亡率的影响:系统评价、Meta分析更新及疾病严重程度亚组Meta分析

Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论Meta分析显示多黏菌素B血液灌流可能降低严重脓毒症和脓毒性休克患者总体死亡率(RR 0.81),中危和高危亚组获益,低危亚组无显著获益。

该系统评价与Meta分析检索PubMed、Embase和Cochrane Library(建库至2016年5月),纳入17项研究多黏菌素B血液灌流对死亡率影响的研究。汇总总体死亡率RR为0.81(95%CI 0.70-0.95,p=0.007),支持多黏菌素B血液灌流。疾病严重程度亚组分析显示中危组(RR 0.84,95%CI 0.77-0.92)和高危组(RR 0.64,95%CI 0.52-0.78)死亡率显著降低,低危组(RR 1.278,95%CI 0.888-1.839)无显著降低。限制性立方样条非线性Meta回归显示基线死亡率与死亡率风险降低之间几乎呈线性负相关。结论认为多黏菌素B血液灌流可能降低特定疾病严重程度亚组严重脓毒症和脓毒性休克患者的死亡率。

要点

  • 汇总17项研究,多黏菌素B血液灌流使严重脓毒症和脓毒性休克患者总体死亡率风险比为0.81(95%CI 0.70-0.95,p=0.007)。
  • 疾病严重程度亚组:中危组死亡率RR 0.84(95%CI 0.77-0.92),高危组RR 0.64(95%CI 0.52-0.78),均显著降低。
  • 低危组死亡率RR 1.278(95%CI 0.888-1.839),无显著降低。
  • 基线死亡率与死亡率风险降低之间几乎呈线性负相关(限制性立方样条非线性Meta回归)。
  • 作者结论:多黏菌素B血液灌流可能降低特定疾病严重程度亚组患者的死亡率。

适用人群与场景

  • 严重脓毒症和脓毒性休克患者(纳入研究的对象)。

研究设计与关键结果

  • 研究类型:系统评价、Meta分析更新及疾病严重程度亚组Meta分析;共纳入17项试验。
  • 检索来源:PubMed、Embase和Cochrane Library,检索时间从建库至2016年5月。
  • 主要终点:总体死亡率汇总风险比0.81(95%CI 0.70-0.95),支持多黏菌素B血液灌流(p=0.007)。
  • 疾病严重程度亚组:中危组死亡率RR 0.84(95%CI 0.77-0.92),高危组RR 0.64(95%CI 0.52-0.78),低危组RR 1.278(95%CI 0.888-1.839)。
  • 非线性Meta回归(限制性立方样条)显示基线死亡率与死亡率风险降低之间几乎呈线性负相关。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(纳入17项试验)。

对床旁实践的改变

  • 作者认为多黏菌素B血液灌流可能降低特定疾病严重程度亚组(中危和高危)严重脓毒症和脓毒性休克患者的死亡率。
  • 低危组未见死亡率显著降低(RR 1.278,95%CI 0.888-1.839)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Several studies have reported a survival benefit for polymyxin B hemoperfusion treatment in patients with severe sepsis and septic shock. However, recently, a propensity-matched analysis and a randomized controlled trial reported no survival benefit for polymyxin B hemoperfusion treatment. We performed an up-to-date meta-analysis to determine the effect of polymyxin B hemoperfusion treatment on mortality in patients with severe sepsis and septic shock.

DATA SOURCES: PubMed, Embase, and Cochrane Library were searched from inception to May 2016.

STUDY SELECTION: Studies investigating the effect of polymyxin B hemoperfusion on mortality were considered eligible. We searched for terms related to severe sepsis and septic shock and terms related to polymyxin B hemoperfusion.

DATA EXTRACTION: The following data were extracted from the original articles: the name of the first author and publication year, subjects and setting, inclusion and exclusion criteria, mean age and size of the study population, male percentage, mortality, blood pressure, Sequential Organ Failure Assessment score, pulmonary oxygenation, and levels of endotoxin and humoral cytokines.

DATA SYNTHESIS: A total of 17 trials were included. The pooled risk ratio for overall mortality was 0.81 (95% CI, 0.70-0.95), favoring polymyxin B hemoperfusion (p = 0.007). Disease severity subgroup meta-analysis revealed a significant reduction of mortality in the intermediate- and high-risk groups (risk ratio, 0.84; 95% CI, 0.77-0.92 and risk ratio, 0.64; 95% CI, 0.52-0.78, respectively), but not in the low-risk group (risk ratio, 1.278; 95% CI, 0.888-1.839). The nonlinear meta-regression with restricted cubic spline showed an almost linear inverse association between the baseline mortality rate and reduction in the risk of mortality.

CONCLUSION: The present study demonstrated that polymyxin B hemoperfusion treatment may reduce mortality in patients with severe sepsis and septic shock in specific disease severity subgroups.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Chang T, Tu YK, Lee CT, et al. Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis. Crit Care Med. 2017. PMID: 28445237. doi:10.1097/CCM.0000000000002362

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。